Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)

Completed

Phase 3 Results

Summary of Purpose

The purpose of this study is to evaluate desmoteplase (which is a manufactured protein derived from the saliva of the vampire bat) in dissolving clots that are blocking the flow of blood through one (or more) of the blood vessels supplying the brain, thereby reopening the blocked blood vessel and allowing blood to flow again in individuals suffering from ischemic stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 19 March 2012.

1 Apr 2005 26 May 2005 1 Mar 2007 Unavailable 1 Mar 2012 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Dr. Anne Spielhofen, Clinical Development PAION Deutschland GmbH Martinstrasse 10-12 52062 Aachen, Germany Email: a.spielhofen@paion.de or dias2@paion.de Tel.: +49-(0)241-4453-0 (switchboard) Fax: +49-(0)241-4453-233

    paul.eng@frx.com